Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)

Patent metadata

Field	Value
Publication number	US-10729665-B2
Application number	US-201214345968-A
Country	US
Kind code	B2
Filing date	Sep 14, 2012
Priority date	Sep 29, 2011
Publication date	Aug 4, 2020
Grant date	Aug 4, 2020

Abstract

This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC). More particularly still the composition is absent or substantially absent of other cannabinoids, including in particular tetrahydrocannabinol (THC) and tetrahydrocannabivarin (THCV), which would normally be present in significant amounts in cannabis chemotypes bred to contain a significant amount of CBDV and/or CBD.

First claim

The invention claimed is:

1. A method for treating epilepsy comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD), absent of the cannabinoids tetrahydrocannabivarin (THCV) and tetrahydrocannabinol (THC), wherein the CBDV and CBD are present in a ratio of from 5:1 to 1:1 (CBDV:CBD).

2. The method of claim 1 , wherein the epilepsy to be treated is generalised seizure.

3. The method of claim 1 , wherein the composition further comprises one or more excipients.

4. The method of claim 1 , wherein the composition further comprises at least one non-cannabinoid component of cannabis.

5. The method of claim 4 , wherein the at least one non-cannabinoid component of cannabis is or comprises a terpene.

6. The method of claim 1 , wherein the phytocannabinoids comprise, or consist essentially of CBDV, CBD and one or more cannabichromene type compounds.

7. The method of claim 6 , wherein the one or more cannabichromene type compounds is cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC).

8. The method of claim 1 , wherein the CBDV and CBD are present in a ratio of 4.5:1 to 2:1 (CBDV:CBD).

9. The method of claim 1 , wherein the composition is a unit dose comprising from 500 to 2000 mg CBDV.

10. The method of claim 9 , wherein the composition is a unit dose comprising from 100 to 600 mg CBD.

11. The method of claim 1 further comprising a standard anti-epileptic drug (SAED).

Assignees

• Whalley Benjamin
• Williams Claire
• Stephens Gary
• Hill Thomas
• Gw Pharma Ltd
• Otsuka Pharma Co Ltd

Inventors

• Whalley Benjamin
• Williams Claire
• Stephens Gary
• Hill Thomas

Classifications

• A61K36/3482

  Cannabis · CPC title

• A61K31/658 Primary

  o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• A61P25/08

  Antiepileptics; Anticonvulsants · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title